The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
Lionel. Great posts. Future looking very bright.
Future is Pharmacogenomics and GDR is well positioned now after years of research and product development now with 2 quality life saving tests to come to market.
Pharmacogenomics market to hit US$40 Billion by 2033. GDR should capture a decent share of it.
BigAl
Good post. Some on this board twisting facts for their own obvious agenda for a lower entry. Some have made it too obvious.
In my own view, we would be raise funds at a higher price from current 6p after some positive updates soon.
Only got 143m shares in issue currently. Lets say they issue another 60m shares @ 10p to raise £6m....that would be circa 200m shares in total.
I will be happy to participate @ 10p and wait for £1.00 when MCap gets to £200m unless bought earlier by Pharma with lowball cheap offer @ 40p
Genedrive is finally on the cusp of generating substantial revenues from its 2 quality products - AIHL tests and STROKE tests.
AIHL being totally exclusive and first to market for Genedrive with NO competition.
GloriaMarket - wild ongoing speculation from you in the past 2 weeks about de-listing and taking company private ???
Far from it - all companies list on AIM to generate funding for Expansion and growth. It takes years for Bio-tech companies to develop breakthrough technology which Genedrive has now got with not one but 2 quality products. Sales will increase substantially as more NHS sites come on board. UK market alone is HUGE for Genedrive before adding Europe, USA, Middle East, Asia Pacific and rest of the world.
Tiger16
Stroke test full NICE recommendation publication date is by 10 July.
But my strong opinion is we could hear headline announcement from NICE soon after 26 April when final Consultation period ends with full report to be published by 10 July.
Will also not rule out a surprise TakeOver approach in the near future soon after STROKE tests recommendation from NICE this year.
Next Operational update / interim results should also confirm increasing Revenues trajectory from AIHL tests before Stroke test Revenues kick in.
Get ready for some updates soon.
Revenues increasing with more take up and additional sites going live.
Update on Stroke Tests full recommendation is going to blow this way way higher in coming weeks.
Full recommendation from NICE could also attract BuyOut opportunities for Big Pharma to take both AIHL and STROKE test market under their wings.
Roger65
Good to see a positive post from you after a long time. Very refreshing. I think there is defo more traction on AIHL and higher take up. NHS despite being slow is finally catching up and we should see higher sales revenues going forward from UK, and hopefully from both Europe and MiddleEast.
Next Operational update should provide more details.
Stroke tests should start generating revenues much earlier than i think. NICE full recommendation is not far now. Public consultation period started May 2023 and about to end on 26 April 2024. Genedrive expect no change in NICE draft recommendation received just recently.
Expect STROKE tests full NICE recommendation news headline soon after 26 April 2024.
Publication date is by 10 July or earlier.
Fully expect this to trickle higher back towards +10p within next 2 weeks ahead of 26 Apr 2024 as punters start taking positions again.
Lionel.
Some very good posts. Very much appreciated by many here. Keep up the good work.
There lot of doom mongers back like Leeches, looking for their lower entry....always a good sign. On top of dealing with Slacker- The Slack and Roger - The dodger.
Consultation period ends on 26 April 2024 in just over 2 weeks.
Full recommendation for STROKE tests by NICE. Expect headline news announcement soon after end of April with full report to be published by 10 July 2024.
This will push higher earlier than some think.
Also very much like detailed analysis by Mr Porsch1 the other day about Genedrive tests could very much be extended to Cardiovascular space also. That would be awesome.
Will be allocating a large chunk of my new ISA allowance here also especially at these prices.
With a potential £200m Buy Out price next year.
UK annual revenues target alone £8.5m potential from AIHL is higher than current £7m MCap. Then add revenues from Europe and rest of the World.
Stroke test revenues will be lot more than this.
Funding overhang stopped the re-rate from last week STROKE tests RNS but probably already arranged and forward sold in my opinion. Just need confirmation. When buying pressure kicks in this moves higher in Half penny increments at lightning speed.
Traders at it again looking for lower entry !!!
Well this is low already....
I think this System fella has lost the plot 🤔
Been nibbling here anything below 6p i think is a fantastic price after last weeks RNS.
Had it not been for the funding overhang we would be over +10p already.
As a general rule of thumb for Annual revenues of circa £10m (to start with)...MCap has to be £100m
Using multipler of 10 as a rough guide.
Justice2u
With you on this one. Rise was held back last week after a superb RNS re STROKE tests mainly due to funding overhang. Once that is out of the way, this is going to rocket higher for a proper rise that has been overdue.
Funding might have been agreed with the broker lets say around 6p (my guess) even though i would have preferred higher. Either way this is going to rocket higher when its done.
Lot of good news still to come. Might be good to get it out of the way for a proper strong rise with NO funding overhang.
Public cnsultation on STROKE tests started in May 2023 and final Consultation period ends on 26 Apr 2024.
NICE publication date of full recommendation is 10 July 2024. I would expect Full recommendation News announcement soon after 26 Apr 2024 with July detailed publication report just a formality.
I would expect a gradual rise between now and 26 April 2024 which is only 3 weeks time as folks start taking positions.
There is already lot of data available for STROKE tests hence will be fast tracked. AIHL was something new and unique to Genedrive being first to market and no competition in this area.
We are on the cusp of revenue generation with potential annual revenues of circa £100m.
Not interested in 2-3p gains here and there. I am looking for much higher and substantial gains in the 60p - 80p bracket. Happy to wait.
I expect a substantial re-rate in price around end of April / start of May towards 20p first target. We got £1.5m cash in bank. They can raise around 15p from investors and end the RF deal for good. That will also allow RF to exercise their 10p warrants which would bring in even more CASH in our bank. By end of Summer we should already be earning revenue from sales.
I repeat 2024 is shaping up to be pivotal year with hugely attractive ROI from 6p upwards. GLA
Taking company private was a dumb / stupid and irrelevant question whichever mor0n asked it. No wonder the reaction.
Whole purpose of listing is to raise funds from the market for growth & expansion of the business as and when required.
Some folks do not understand the basics. Traders jumped on that in the heat of the moment creating unnecessary volatilty for their own gain.
I expect Genedrive to also list in USA at some point in the future. US investors have far bigger appetite for bio-tech stocks like Genedrive especially with POC pharmacogenetics being the future.
Good thing is company does not want to use RF deal anymore and looking to replace it with good old standard placing with retail investors down the road probably at a higher price giving also RF a chance to exercise their 10p warrants etc.
Further updates/RNS in coming days/ weeks should be more revealing.
I thought presentation overall was fine.
There will more news.
Some folks who sold higher talking it down.
Roger the dodger...though you were already out.
Genedrive has ZERO debt.
If they get a lowball cheap Buy Out offer of £50m or £100m
Sale proceeds go to SHAREHOLDERS coz there are NO DEBT HOLDERS.
Public or Private is red herring and Offtopic.